The companies were showcasing lung cancer data from their two rival blockbuster ... tumour mutation burden (TMB) in its latest studies. The combination tripled progression-free survival at one ...

but it finally has a positive result in lung cancer. In the POSEIDON trial, triple therapy with PD-L1 inhibitor Imfinzi (durvalumab), CTLA4 inhibitor tremelimumab and a choice of chemotherapy ...

Nelmastobart (hSTC810) combined with capecitabine therapy in metastatic colorectal cancer with resistance or intolerance to oxaliplatin and irinotecan-based chemotherapy: A phase 1b clinical trial.

The assay will identify patients with six cancer types, namely solid tumours, breast cancer, colorectal cancer (CRC), ...